The BM niche comprises a tightly controlled microenvironment formed by specific tissue and cells that regulate the behavior of hematopoietic stem cells (HSCs). Here, we have provided a 3D model that is tunable in different BM niche components and useful, both in vitro and in vivo, for studying the maintenance of normal and malignant hematopoiesis. Using scaffolds, we tested the capacity of different stromal cell types to support human HSCs. Scaffolds coated with human mesenchymal stromal cells (hMSCs) proved to be superior in terms of HSC engraftment and long-term maintenance when implanted in vivo. Moreover, we found that hMSC-coated scaffolds can be modulated to form humanized bone tissue, which was also able to support human HSC engraftment. Importantly, hMSC-coated humanized scaffolds were able to support the growth of leukemia patient cells in vivo, including the growth of samples that would not engraft the BM of immunodeficient mice. These results demonstrate that an s.c. implantation approach in a 3D carrier scaffold seeded with stromal cells is an effective in vivo niche model for studying human hematopoiesis. The various niche components of this model can be changed depending on the context to improve the engraftment of nonengrafting acute myeloid leukemia (AML) samples.

Introduction
The BM niche comprises a tightly controlled microenvironment formed by various cell types that regulate the behavior of hematopoietic stem cells (HSCs). Currently, i.v. injection of cells in immunodeficient mouse models, followed by cellular studies of murine BM tissue, is the most common assay for studying normal and malignant human hematopoiesis. Although successful engraftment of primary acute myeloid leukemia (AML) is achievable, our own lab and others have shown that not all AML samples are able to engraft immunodeficient mice and that the engraftment ability of these samples is related to their clinical outcome (1–3). Over the past few years, this has prompted the development of new mouse strains encoding human cytokines and has also opened the door to a novel approach. By merging knowledge from biomaterials, tissue engineering, and cell-implantation fields, investigators have generated new models to mimic the native human hematopoietic microenvironment within s.c. 3D structures (4–5). Using human mesenchymal stromal cells (hMSCs) as stromal cell support within bone-forming implants, researchers have studied normal (6–10) and malignant (11–16) hematopoiesis.

In this context, we focused on the development of an implantable tool whereby different niche components could be tested, both in vitro and in vivo, in order to study both normal and malignant primary human hematopoietic cells.

Results and Discussion
Preliminary assays were performed using different scaffold materials and various cell-seeding methods (data not shown). We found that injecting a stromal cell suspension into the center of a partially dehydrated gelatin-based porous scaffold (Gelfoam) provided a consistent coverage throughout the material (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI89364DS1). Further seeding of human hematopoietic cells using the same technique allowed adherence to preseeded stromal cells (Supplemental Figure 1), suggesting that this approach could be useful for hematopoietic cell studies. Importantly, the flexible nature of the selected biocompatible cell-carrier scaffold facilitates sectioning to the desired size via simple cutting while also allowing effective digestion using collagenase, meaning easy access to the cells for further studies. Next, we evaluated the supportiveness of mesenchymal, endothelial, or osteoblastic niche cells for the maintenance of human cord blood–derived hematopoietic stem and progenitor cells (CB-HSPCs) within the 3D model both in vitro and in vivo (Supplemental Figure 2). In vitro, most of the tested stromal cells promoted robust growth of all primary hematopoietic colony lineages (Supplemental Figure 2, B and C). In vivo, despite the detection of multilineage human engraftment in most stroma-seeded scaffolds, the hMSC-coated scaffolds had a significantly ($P < 0.0001$) (Supplemental Figure 2E, Left panel) higher capacity for maintaining human hematopoietic cell engraftment in primary mice. Using a secondary transplantation assay, we observed engraftment only with cells recovered from human osteoblast-, endothelial- and MSC-seeded scaffolds (Supplemental Figure 2E). Therefore, based on primary and secondary transplant...
assays, we decided to use hMSCs for further studies. Single-donor-derived hMSCs were used to test CB-HSPC interdonor variability in vivo (Figure 1). Although we found no significant differences in human hematopoietic cell engraftment, we did observe disparity in myeloid and lymphoid lineage distribution outcome between cord bloods (Figure 1, A and B respectively). Furthermore, hMSC intradonor variability was also tested meaning the engraftment of single-donor CB-HSPCs in scaffolds with hMSCs from different donors (Figure 1C), indicating interdonor hMSC variability, while lineage distribution was similar for all tested cells, which in this case was mainly myeloid (Figure 1D).
Following this, we evaluated different methods of seeding hHSPCs into the scaffold: either (a) preseeding hHSPCs before implantation; (b and c) first implanting the hMSC scaffold and then injecting the hHSPCs; or (d) injecting hHSPCs directly into the scaffold (Supplemental Figure 2A). We quantified whether bone formation within the implanted scaffolds would affect hematopoietic cell engraftment and therefore added BMP-2, an osteoinductive growth factor, to the implanted material (see Figure 1). This approach yielded s.c. bone formation with vascularized BM and hMSCs, which had differentiated into adipose and osteoblastic lineages (Figure 1, J–N). Moreover, human hematopoietic cells had also engrafted the newly formed mature BM tissue (Figure 1O).

Interestingly, we observed that mouse hematopoietic cells migrated into the implanted scaffolds (Supplemental Figure 3), while vascularization of the scaffolds was observed using intravital microscopy (Supplemental Figure 4A). Additionally, histological characterization revealed some hCD45-positive cells next to vascular structures within the scaffolds (Supplemental Figure 4B). We also looked for the presence of hMSCs in the recovered scaffold (Supplemental Figure 5). Histology showed Vimentin expressing cells in scaffolds, while we were able to recover cells with hMSC phenotype from scaffolds (Supplemental Figure 3 and 5). None of the implanted scaffolds showed evidence of calcification (Figure 1, E and F), whereas a small portion of implanted hMSCs had differentiated to osteolineage (osterix+, Figure 1H, or osteocalcin+, Supplemental Figure 5B).

We questioned whether bone formation within the implanted scaffolds would affect hematopoietic cell engraftment and therefore added BMP-2, an osteoinductive growth factor, to the implanted material (see Figure 1). This approach yielded s.c. bone formation with vascularized BM and hMSCs, which had differentiated into adipose and osteoblastic lineages (Figure 1, J–N). Moreover, human hematopoietic cells had also engrafted the newly formed mature BM tissue (Figure 1O).

Next, we chose the preseeded protocol to test whether the “humanized” scaffolds were able to maintain AML patient samples in vivo. We selected a cohort of 15 AML patients (Supplemental Table 1), which included patients previously tested and classified as high engrafters (≥1%), low engrafters (1%–0.1%), and nonengrafters (<0.1%) within the conventional i.v. transplantation model using NSG mice.

We generally observed a comparable or superior level of engraftment in the 2-scaffold–implanted models (SC and BSC) compared with conventional i.v. injection in all high- or low-engrafted samples tested (8 out of 8 in the scaffold-implanted model versus 4 out of 5 in the bone scaffold–implanted model) (Figure 3A), with mainly no to little engraftment in host BM (Supplemental Figure 7), except when higher AML cell doses were seeded in the scaffold (see Supplemental Figure 7, B and C). Importantly, leukemic engraftment of the nonengrafters was exclusively observed in the scaffold models (7/7 cases in the scaffold-implanted model versus 3/6 in the bone scaffold–implanted model) (Figure 3A). In order to compare and track the AML burden in the xenotransplantation model.
models, a panel of 24 genes, commonly mutated in myeloid malignancies, was used to screen hCD33+ pretransplanted cells obtained at day 0 from all patients (Table 1). Following on, patient-specific targeted mutation screen was performed on the posttransplanted cells. Analysis showed that in the implanted scaffolds, leukemic burden was largely maintained compared to the preimplanted patient cells, indicating that the scaffold model retained the original clonal architecture (Figure 3B and Supplemental Table 2). Finally, we tested to determine whether the leukemic cells present in these scaffolds (see absolute number of cells retrieved/mouse, Supplemental Figure 8) had leukemic stem cell capacity by performing secondary transplantation. For patients 1 and 2, which were high engrafters, we observed similar secondary engraftment whatever model was used, whereas for patients 4 and 9 (low engrafter and nonengrafter, respectively), secondary engraftment was only successful in the scaffold models. Interestingly, in this case, samples from primary scaffolds were not able to engraft the BM of secondary mice when transplanted i.v., suggesting their dependence on a humanized environment for their growth (Figure 3C).

Overall, our work describes a versatile humanized niche model for studying both normal and leukemic human hematopoietic cell biology, particularly for the less aggressive subtypes that fail to engraft in NSG mice. Recent reports demonstrate the use of humanized bone ossicles for the study of malignant hematopoiesis (11–16). Nevertheless, in all of these models, hMSCs were first induced to form bone ossicles before malignant hematopoietic cells were injected intrascaffold, making the duration of the whole experiment between 20 and 34 weeks compared with only 10 to 12 weeks in our study. Importantly, our data demonstrate that bone formation is not mandatory for human normal and leukemic engraftment, contrary to what was previously described (18, 19). Moreover, the flexibility of our reported approach should also help to decipher the role of different human stromal cell types (normal or malignant hMSCs or even comparing in vivo hMSC versus human endothelial cells.
versus osteoblasts) as well as the importance of particular signaling pathways within the hematopoietic niche, using genetically modified stromal cells to dissect the crosstalk between normal and/or leukemic human hematopoietic cells and their stroma. This model could also be used to screen drugs, specifically those that target stromal components.

Methods

Additional methods and associated references are available in the Supplemental Methods.

Study approval. All animal experiments were performed under license PPL 70/8904 approved by the Home Office of the United Kingdom and in accordance with Cancer Research UK guidelines. The use of umbilical cord blood (UCB) and AML samples was approved by the East London Ethical Committee and carried out in accordance with the Declaration of Helsinki.

Statistics. Prism Version 6 software (GraphPad) was used for statistical analysis. Data are presented as mean ± SEM. To determine the level of significance, statistical analysis was performed using either a Dunnett’s test for comparison of 2 groups or using a Tukey’s ANOVA test for multiple comparisons. A P value of less than 0.05 was considered significant.

Author contributions

AA, KF, and AH performed the research, analyzed data, and wrote the manuscript. SAM performed molecular analysis and analyzed results. JG provided AML samples and relevant patient information. GM provided the sequencing analysis before and after xenotransplantation. DB directed the research, analyzed data, and wrote the manuscript. DP performed research and analyzed data. All authors approved the manuscript.

Acknowledgments

We thank staff of the core facilities at the Francis Crick Institute (Biological Research Facility, Flow Cytometry, Experimental Histopathology, In Vivo Imaging, Electron Microscopy, and Cryo-Electron Microscopy) for their valuable help. This work was supported by The Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001045), the UK Medical Research Council (FC001045), and the Wellcome Trust (FC001045).

Address correspondence to: Dominique Bonnet, The Francis Crick Institute, 1 Midland Road, NW1 1AT, London, United Kingdom. Phone: 44.0.203761198; E-mail: dominique.bonnet@crick.ac.uk.


